ArticleTherapeutic advances in medical oncology2022
Efficacy and safety of selpercatinib in Chinese patients with advanced
Article in Therapeutic advances in medical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04280081 (A Phase 2 Study of Oral Selpercatinib), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Who cites it
14 citing papers in PubMed.
- Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib.Frontiers in oncology · 2026Article
- First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia WithJTO clinical and research reports · 2025Article
- AdvancingTranslational cancer research · 2025Article
- Evolution of treatment strategies for solid tumors with RET rearrangement in China and real-world treatment status of Non-small Cell Lung Cancer (NSCLC).BMC pulmonary medicine · 2024Article
- Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.Cell communication and signaling : CCS · 2024Review
- Efficacy and safety of selpercatinib in treating RET-altered MTC: A single-arm meta-analysis.Heliyon · 2024Article
- Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies.Frontiers in endocrinology · 2024Review
- Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers.Cell reports. Medicine · 2023Review
- Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea.Current oncology (Toronto, Ont.) · 2023Article
- Hereditary cancer syndromes.World journal of clinical oncology · 2023Review
- Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect.International journal of molecular sciences · 2023Review
- A comprehensive overview of the relationship between RET gene and tumor occurrence.Frontiers in oncology · 2023Review
- Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib inFrontiers in oncology · 2023Article
- RET signaling pathway and RET inhibitors in human cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Selpercatinib, a highly selective and potent REarranged during Transfection (RET) kinase inhibitor, is effective in advanced Patients and methods: In the open-label, multi-center phase II LIBRETTO-321 (NCT04280081) study, Chinese patients with advanced solid tumors harboring Results: Of 77 enrolled patients, 29 had Conclusions: Selpercatinib showed robust antitumor activity and was well tolerated in Chinese patients with advanced ClinicalTrialsgov Identifier: NCT04280081 (first posted Feb 21, 2020).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.